Kieren Mather, MDAssociate VP-Medical-Incretins and Diabetes Breakthroughs, Early Clinical Research at Eli Lilly and CompanySpeaker
Profile
Dr. Mather trained in Endocrinology in Canada. Following a 20 year academic career focused on studies of metabolic physiology and clinical trials in diabetes, he joined Eli Lilly and Company in 2020. He oversees clinical studies for the early phase portfolio of incretins and related molecules with actions in glucose and weight management.
Agenda Sessions
GLP-1 Clinical Progress, Pipeline and Innovation
, 3:30pmView Session